Dublin, May 08, 2023 (GLOBE NEWSWIRE) -- The "Glioma - Competitive Landscape, 2023" report has been added to ResearchAndMarkets.com's offering.
This "Glioma - Competitive landscape, 2023" report provides comprehensive insights about 200+ companies and 220+ drugs in Glioma Competitive landscape.
It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Glioma treatment is customized to the individual patient and may include surgery, radiation therapy, and chemotherapy. Even after surgery recurrence, the rate is quite higher for glioma patients. Although there have been recent advances in the diagnosis and treatment of malignancy, the prognosis of gliomas is still poor, especially for those patients with malignant and invasive gliomas.
Report Highlights
In February 2023, Kite, a Gilead Company announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.
In February 2023, Genenta Science entered into a development and manufacturing service agreement (MSA) with AGC Biologics S.p.A. to manufacture cell therapy lentivirus-based product for Genenta's ongoing clinical programs. AGC Biologics offers end-to-end global viral vector and cell therapy development, manufacturing, and quality/regulatory services, supported by scientists with more than 30 years of knowledge and experience.
In October 2022, ITM Isotope Technologies Munich SE announced the execution of an exclusive licensing option for LuCaFab (now ITM-31), a novel Targeted Radionuclide Therapy candidate for the treatment of malignant glioblastoma.
In October 2022, VBI Vaccines Inc., and Agenus, announced a collaboration to evaluate the combination of VBI-1901, in primary glioblastoma (GBM) patients as part of the adaptive platform trial, INSIGhT.
In September 2022, Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, and Day One Biopharmaceuticals a clinical-stage biopharmaceutical company announced a collaboration to develop FoundationOneCDx as a companion diagnostic for Day One's lead investigational therapy, tovorafenib (DAY101). If tovorafenib, and Foundation Medicine's companion diagnostic are approved, this would be the first companion diagnostic indication for FoundationOne CDx in pediatric oncology.
In September 2022, Merck announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l. (NMS) for NMS-293. Under the current agreement, Merck will make early payments (up-front and option exercise fees) of up to US$65 million to NMS.
Furthermore, NMS will receive payments for the achievement of certain development, regulatory and commercial milestones and tiered royalties on net sales by Merck. Upon exercise of the option, NMS will grant to Merck the exclusive rights to research, develop, manufacture, and commercialize NMS-293.
In-depth Commercial Assessment: Glioma Collaboration Analysis by Companies
The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Glioma drugs?
- How many Glioma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glioma?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Glioma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Glioma and their status?
- What are the key designations that have been granted to the emerging and approved drugs?
Key Players
- Denovo Biopharma
- AstraZeneca
- Pfizer
- Chimerix
- Bristol-Myers Squibb
- Orbus Therapeutics
- Northwest Biotherapeutics
- Day One Biopharmaceuticals
- AiVita Biomedical
- Ascletis Pharma Inc
- Kazia Therapeutics
- HebaBiz Biotech
- Biohaven Pharmaceuticals
- Vigeo Therapeutics
- Hoffman-La-Roche
- TVAX Biomedical
- Laminar Pharmaceuticals
- Kintara Therapeutics
- Medicenna Therapeutics
- Symphogen A/S
- MimiVax
- Incyte Corporation
- Istari Oncology
- Immunomic Therapeutics
- Sanofi
- Merck Sharp & Dohme LLC
- Oblato, Inc.
- GlaxoSmithKline
- NuvOx Pharma
- Epitopoietic Research Corporation
- AnHeart Therapeutics
- DNAtrix
- Arog Pharmaceuticals
- CANbridge Pharmaceuticals
- Jiangsu Hengrui Medicine
- BPGbio, Inc.
- BioMimetix
- CNS Pharmaceuticals
- Ever Supreme Bio Technology
- Chia Tai Tianqing Pharmaceutical Group
- CytoVac
Key Products
- Enzastaurin
- Selumetinib
- Tofacitinib
- ONC201
- Opdivo
- Eflornithine
- DCVax-L
- DAY101
- AV-GBM-1
- ASC40
- Paxalisib
- JP001
- Troriluzole
- VT1021
- Vemurafenib
- TVI-Brain-1
- LAM561
- VAL-083
- MDNA55
- Sym004
- SurVaxM
- Retifanlimab
- PVSRIPO
- LAMP-pp65-DC
- Plerixafor
- Pembrolizumab
- OKN-007
- Niraparib
- NanO2
- ERC1671
- AB-218
- DNX-2401
- Crenolanib
- CAN008
- Camrelizumab
- BPM 31510
- BMX-001
- Berubicin
- ADCV01
- Anlotinib
- ALECSAT
For more information about this report visit https://www.researchandmarkets.com/r/wxdutn
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
